Bernstein analyst Eve Burstein raised the firm’s price target on Exact Sciences (EXAS) to $90 from $75 and keeps an Outperform rating on the shares. With the large, diversified tools companies taking a hit this earnings season, the firm sees the diagnostics names as the safe place to be in the sector. Broadly, reimbursement tailwinds from the biomarker bills continue to help ASPs in the sector, with California’s bill now live and the introduction of a new bill from Hawaii. On the regulatory front, the FDA LDT regulation was enacted in Q2, though legal challenges have been mounting as expected, Bernstein adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target raised to $95 from $75 at Canaccord
- Exact Sciences announces FDA approval of Cologuard Plus test
- Exact Sciences price target raised to $80 from $72 at Evercore ISI
- Exact didn’t get Cologuard Plus price hike in preliminary CLFS, says Wolfe
- Exact Sciences price target raised to $82 from $70 at BTIG